Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 37 citing articles:

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 44
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 17
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 33
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Sarah E. Smith-Jeffcoat, Jessica E Biddle, H. Keipp Talbot, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1175-1184
Open Access | Times Cited: 22
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
Dallas J. Smith, Anastasia S. Lambrou, Pragna Patel
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1357-1364
Open Access | Times Cited: 21
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Jeremy Samuel Faust, Ashish Kumar, Jui Shah, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1257-1264
Closed Access | Times Cited: 18
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
Patrick R. Harrington, Jie Cong, Stephanie B. Troy, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 51, pp. 1365-1370
Open Access | Times Cited: 13
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Carlos King Ho Wong, Jonathan J. Lau, Ivan Chi Ho Au, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action
A. Chiarelli, Hana M. Dobrovolny
Interdisciplinary Sciences Computational Life Sciences (2024) Vol. 16, Iss. 4, pp. 844-853
Closed Access | Times Cited: 3
Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
Pao-Yu Chen, Jann‐Tay Wang, Sui‐Yuan Chang, et al.
Journal of the Formosan Medical Association (2023) Vol. 122, Iss. 8, pp. 766-775
Open Access | Times Cited: 8
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 8
Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro
Manoj S. Nair, Maria I. Luck, Yaoxing Huang, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 2
SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults
Matthew E. Levy, Evanette Burrows, Vanessa Chilunda, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 6, pp. 1531-1535
Closed Access | Times Cited: 5
Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
Daniel M. Camp, Matthew Caputo, Fabiola Moreno Echevarria, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Coronavirus Disease 2019 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: A Prospective Cohort Study
Jacqueline K. Kueper, Kalyani Kottilil, Giorgio Quer, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
Shadisadat Esmaeili, Katherine Owens, Jessica Wagoner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
F Panza, Fabio Fiorino, G Pastore, et al.
Microorganisms (2023) Vol. 11, Iss. 10, pp. 2607-2607
Open Access | Times Cited: 3
Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?
William A. Werbel, Ethel D. Weld, Sonali Advani, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 1, pp. 32-37
Open Access | Times Cited: 2
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top